Skip to content
OpenCapital
Get started

Danaher DHR Life Sciences — Capital expenditures, gross

Other segment segments

Diagnostics
$195M—
Biotechnology
$66M-17.5%

Similar metrics at other companies

VAT
VATELife Sciences — Capital cash expenditures
$0-100%
GLW
GLWLife Sciences and Emerging Growth Businesses — CapEx
$5M-37.5%
Thermo Fisher Scientific logo
TMOLife Sciences Solutions — Purchases of property, plant and equipment
$20M-53.5%
RCM Technologies logo
RCMTLife Sciences Data Solutions — Segment Expenditure Addition To Long Lived Assets
$0-100%
Ashland logo
ASHLife Sciences — Segment Expenditure Addition To Long Lived Assets
$12.25M-19.7%
VAT
VATELife Sciences — Investments
$1.8M0.0%

Other financials

Income statement

See full
Revenue$6.3B+5.5%
Gross profit$3.6B+2.5%
Operating income$1.1B+48.3%
Net income$870.0M+56.8%
EPS (diluted)$1.23+59.7%

Balance sheet

See full
Cash & equivalents$4.3B+47.0%
Total debt$27.9B+50.1%
Total equity$52.6B+0.5%
Total assets$92.4B+13.2%

Cash flow

See full
Operating cash flow$1.5B+14.6%
CapEx$269.0M+8.5%
Free cash flow$1.3B+16.1%

Valuation

See full
Market cap$134.62B-7.4%
Enterprise value$158.13B-1.7%
P/E33.6×-9.0×
P/S5.4×-0.7×

Profitability

See full
Gross margin58.5%-1.1pp
Operating margin20.4%+2.0pp
Net margin15.9%+1.7pp
FCF margin21.8%+1.5pp

Returns & leverage

See full
Return on equity7.6%+1.0pp
Debt / equity0.5×+0.2×
Current ratio1.7×0.0×

Where this comes from

Reported directly by Danaher in its filing.

Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.

The official record: Danaher’s 10-Q, filed July 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Danaher's life sciences — capital expenditures, gross.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Danaher's life sciences — capital expenditures, gross?
Danaher (DHR) reported life sciences — capital expenditures, gross of $38M in Q2 2026.
How has Danaher's life sciences — capital expenditures, gross changed year-over-year?
Danaher's life sciences — capital expenditures, gross decreased by 7.3% year-over-year, from $41M to $38M.
What is the long-term trend for Danaher's life sciences — capital expenditures, gross?
Over 2 years (2023 to 2025), Danaher's life sciences — capital expenditures, gross has grown at a -23.8% compound annual growth rate (CAGR), from $320M to $186M.
What does life sciences — capital expenditures, gross mean?
The total cash outflow for the acquisition or improvement of long-term physical assets within the Life Sciences segment. This represents the investment in manufacturing capacity, R&D facilities, and infrastructure required to support future growth. It is a key indicator of management's commitment to long-term operational expansion.